Conference report: Trends, new technologies and implications for dementia diagnostics, treatment and care in Switzerland

Dementia diseases represent a major burden for the directly affected people, their relatives and modern society. Despite considerable efforts in recent years, early and accurate disease diagnosis and monitoring is still a challenge while no cure is available in most cases. New drugs, in particular disease-modifying therapies, and recent technological advancements offer promising perspectives. The integration of novel biomarkers, artificial intelligence and digital health tools has the potential to transform dementia care, making it more personalised, efficient and adapted to the living conditions and needs of older people. In November 2023, the 7th Dementia Summit convened a panel of experts from geriatrics, neurology, neuropsychology, psychiatry, ethics as well as general medicine to discuss interdisciplinary challenges, advancements and their implications for the future of dementia care in Switzerland. The conference underscored the importance of a multidisciplinary approach to successfully integrate new technologies in both clinical-translational research and dementia prevention, diagnosis and care. While recent innovations represent major steps forward, their implementation also comes with important challenges including questions on healthcare system preparedness and adaptation, ethical aspects, technology literacy, acceptance and appropriate use.

Authors

Institutions

Publication Details

Journal
Swiss Medical Weekly
Published
2025-03-26
DOI
https://doi.org/10.57187/s.4017
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Conference report: Trends, new technologies and implications for dementia diagnostics, treatment and care in Switzerland

Stefan Klöppel, Andreas U. Monsch, Julius Popp, Tatjana Meyer-Heim et al.
Swiss Medical Weekly
Dementia and Cognitive Impairment Research
article

Conference report: Trends, new technologies and implications for dementia diagnostics, treatment and care in Switzerland

Stefan Klöppel, Andreas U. Monsch, Julius Popp, Tatjana Meyer-Heim, Miriam Rabl, Hans Pihan, Mélanie Bieler-Aeschlimann, Marcello Ienca, Reto W. Kressig, Stefanie Becker
article en

Abstract

Dementia diseases represent a major burden for the directly affected people, their relatives and modern society. Despite considerable efforts in recent years, early and accurate disease diagnosis and monitoring is still a challenge while no cure is available in most cases. New drugs, in particular disease-modifying therapies, and recent technological advancements offer promising perspectives. The integration of novel biomarkers, artificial intelligence and digital health tools has the potential to transform dementia care, making it more personalised, efficient and adapted to the living conditions and needs of older people. In November 2023, the 7th Dementia Summit convened a panel of experts from geriatrics, neurology, neuropsychology, psychiatry, ethics as well as general medicine to discuss interdisciplinary challenges, advancements and their implications for the future of dementia care in Switzerland. The conference underscored the importance of a multidisciplinary approach to successfully integrate new technologies in both clinical-translational research and dementia prevention, diagnosis and care. While recent innovations represent major steps forward, their implementation also comes with important challenges including questions on healthcare system preparedness and adaptation, ethical aspects, technology literacy, acceptance and appropriate use.

Swiss Medical WeeklyVol. 155(3)
University of Bern (CH), University of Basel (CH), University of Zurich (CH), Centre Hospitalier Universitaire Vaudois (CH), University Hospital of Zurich (CH), Felix Platter-Hospital (CH), Stadtspital Waid (CH), Spitalzentrum Centre hospitalier Biel- Bienne (CH), École Polytechnique Fédérale de Lausanne (CH), Technical University of Munich (DE)
Eli Lilly and Company, Biogen, Eisai, Merz Pharmaceuticals, H. Lundbeck A/S
Quality Education
Openalex Percentile: Top 93%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.